Matsumoto T, Furukawa A, Sumiyoshi Y, Akiyama K Y, Kanayama H O, Kagawa S
Department of Urology, Taijukai Kaisei Hospital, Sakaide, Japan.
Urology. 1998 Jan;51(1):145-9. doi: 10.1016/s0090-4295(97)00476-7.
To evaluate increased serum soluble interleukin-2 receptor (sIL-2R) levels in patients with renal cell carcinoma (RCC).
Serum sIL-2R levels were measured in 52 patients with RCC and 10 control subjects by an enzyme-linked immunosorbent assay (ELISA) technique. The correlation between serum sIL-2R levels and clinical stage, disease prognostic value, and inflammatory marker levels was analyzed.
Serum sIL-2R levels in patients with RCC were significantly higher than those in normal control subjects (857.2 +/- 660.0 versus 291.3 +/- 76.4 U/mL, P < 0.0001). High serum sIL-2R levels appeared to be related to advanced clinical stage (596.0 +/- 276.5 U/mL in Stage II, 776.1 +/- 398.8 U/mL in Stage III, and 1310.0 +/- 926.7 U/mL in Stage IV: Stage II vs. Stage III, P = 0.0078; Stage II vs. Stage IV, P < 0.0001). The overall cause-specific survival curves showed that patients with high sIL-2R levels (more than 1000 U/mL) had a significantly lower survival rate than those with low (less than 500 U/mL, P = 0.0003) or intermediate levels (500 to 1000 U/mL, P = 0.0007). C-reactive protein levels apparently increased in patients with high sIL-2R concentrations.
Measurement of serum sIL-2R concentrations in patients with RCC provides useful information for predicting the extent of disease and length of survival.
评估肾细胞癌（RCC）患者血清可溶性白细胞介素-2受体（sIL-2R）水平升高情况。
采用酶联免疫吸附测定（ELISA）技术，对52例RCC患者和10例对照者的血清sIL-2R水平进行检测。分析血清sIL-2R水平与临床分期、疾病预后价值及炎症标志物水平之间的相关性。
RCC患者的血清sIL-2R水平显著高于正常对照者（857.2±660.0对291.3±76.4 U/mL，P<0.0001）。高血清sIL-2R水平似乎与晚期临床分期相关（Ⅱ期为596.0±276.5 U/mL，Ⅲ期为776.1±398.8 U/mL，Ⅳ期为1310.0±926.7 U/mL：Ⅱ期与Ⅲ期比较，P = 0.0078；Ⅱ期与Ⅳ期比较，P<0.0001）。总体病因特异性生存曲线显示，sIL-2R水平高（超过1000 U/mL）的患者生存率显著低于水平低（低于500 U/mL，P = 0.0003）或中等（500至1000 U/mL，P = 0.0007）的患者。高sIL-2R浓度患者的C反应蛋白水平明显升高。
检测RCC患者血清sIL-2R浓度可为预测疾病范围和生存时长提供有用信息。
